Advertisement


Shauna Campbell, DO, on Head and Neck Cancer: Toxicity Associated With Hypofractionated IMRT

2021 ASTRO Annual Meeting

Advertisement

Shauna Campbell, DO, of Cleveland Clinic, discusses results from her study that showed hypofractionated intensity-modulated radiation therapy (H-IMRT) in the definitive or postoperative treatment of head and neck cancers using ≥ 50 Gy in 20 fractions appears to be safe and well tolerated with modest toxicity. Dr. Campbell suggests that prospective studies comparing the safety and efficacy of H-IMRT with those of conventionally fractionated IMRT are warranted (Abstract 2313).



Related Videos

Prostate Cancer

Mark K. Buyyounouski, MD, MS, on Prostate Cancer: Hypofractionated vs Conventional Radiotherapy After Surgery

Mark K. Buyyounouski, MD, MS, of Stanford University, discusses phase III results from the NRG Oncology GU003 trial, which showed that, post-prostatectomy, using fewer—but higher—doses of radiation does not appear to increase long-term side effects or reduce quality of life when compared with conventional radiation treatment (Abstract 3).

CNS Cancers
Genomics/Genetics

Diana D. Shi, MD, on IDH-Mutant Gliomas: De Novo Pyrmidine Synthesis Inhibitor Under Study

Diana D. Shi, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Cancer Center, discusses studies being planned and already underway to test BAY 2402234, a de novo pyrimidine synthesis inhibitor that possibly could be used clinically to target IDH-mutant gliomas and may act as a tumor-selective radiosensitizer (Abstract 167).

Solid Tumors

Aadel A. Chaudhuri, MD, PhD, on Personalizing Treatment for Oligometastatic Cancer

Aadel A. Chaudhuri, MD, PhD, of Washington University School of Medicine in St. Louis, discusses circulating tumor DNA, which has the potential to better personalize treatment for patients with oligometastatic cancer and help clinicians determine whether to offer systemic therapy alone or curative-intent local consolidative therapy.

Issues in Oncology

Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for widespread disease might improve survival and lead to a cure.

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses whether hypofractionation can be safely employed in the post-prostatectomy setting and the role of short-term hormone therapy in the management of intermediate-risk prostate cancer with radiotherapy.

Advertisement

Advertisement




Advertisement